Discontinued — last reported Q4 '23
Products & Services · Deferred revenues
Comirnaty — Deferred revenues
Pfizer Comirnaty — Deferred revenues decreased by 46.9% to $1.7B in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 32.0%, from $2.5B to $1.7B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2020
Last reportedQ4 2023Feb 22, 2024
Rolls up toContract Liabilities
How to read this metric
An increase indicates strong future revenue potential as performance obligations are met, while a decrease may signal a slowdown in new orders.
Detailed definition
Payments received from customers for Comirnaty products for which the performance obligations have not yet been satisfie...
Peer comparison
Common in industries with large-scale government contracts or advance purchase agreements.
Metric ID:
pfe_segment_comirnaty_deferred_revenuesHistorical Data
7 periods
| Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $3.7B | $3.3B | $2.5B | $1.7B | $1.2B | $3.2B | $1.7B |
| QoQ Change | — | -10.8% | -24.2% | -32.0% | -29.4% | +166.7% | -46.9% |
| YoY Change | — | — | -24.2% | — | — | — | -32.0% |
Range$1.2B – $3.7B
CAGR-40.5%
Avg YoY Growth-28.1%
Median YoY Growth-28.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's comirnaty — deferred revenues?
- Pfizer (PFE) reported comirnaty — deferred revenues of $1.7B in Q4 2023.
- How has Pfizer's comirnaty — deferred revenues changed year-over-year?
- Pfizer's comirnaty — deferred revenues decreased by 32.0% year-over-year, from $2.5B to $1.7B.
- What does comirnaty — deferred revenues mean?
- Cash received for Comirnaty products where the revenue has not yet been earned.